GO:0019958 C-X-C chemokine binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0019958 defines the molecular function of binding to C-X-C chemokines, a subclass of chemokines with one amino acid between the first two cysteines of the four-cysteine motif.
• C-X-C chemokine binding is mediated by both classical G-protein-coupled receptors and atypical decoy receptors such as the Duffy antigen receptor for chemokines (DARC).
• Pathogens and parasites have evolved C-X-C chemokine-binding proteins, such as tick evasins and viral chemokine-binding proteins, to evade host immunity.
• C-X-C chemokine binding regulates leukocyte trafficking, angiogenesis, and tumor microenvironment remodeling, with implications for cancer, osteoarthritis, and inflammatory diseases.
• Experimental methods to study C-X-C chemokine binding include in situ binding assays, surface plasmon resonance, and chemokine-receptor interaction assays.
• CRISPR-based models (knockout, knock-in, overexpression) enable causal interrogation of genes encoding C-X-C chemokines, their receptors, and binding proteins.
Description
C-X-C chemokine binding (GO:0019958) is a molecular function that describes the selective interaction of a protein with C-X-C chemokines, a subgroup of chemokines characterized by a single amino acid separating the first two cysteines of the conserved four-cysteine motif. This binding event is fundamental to immune cell recruitment, tissue repair, and host defense, and it is mediated by a diverse set of proteins including G-protein-coupled receptors, atypical chemokine receptors, and pathogen-derived decoy proteins. Understanding the specificity and regulation of C-X-C chemokine binding is critical for deciphering inflammatory and malignant processes. For example, the Duffy antigen receptor for chemokines (DARC) binds both C-X-C and C-C chemokines, but with distinct affinities that influence chemokine bioavailability. In cancer, tumor-associated macrophages can promote chemoresistance through an intercellular CXCL17/CXCL22-CCR4-ATF6-GRP78 axis, highlighting the pathological relevance of C-X-C chemokine binding. Moreover, tick evasins have been engineered to selectively bind C-X-C chemokines, offering tools for therapeutic intervention. Researchers studying this term often need to determine which proteins bind C-X-C chemokines, how binding specificity is achieved, and how these interactions can be targeted in disease. This article synthesizes authoritative QuickGO data and verified PubMed literature to provide a research-grade overview of GO:0019958, covering its definition, mechanism, key genes, disease associations, and experimental approaches.
C-X-C chemokine binding At A Glance
| GO ID | GO:0019958 |
|---|---|
| GO term | C-X-C chemokine binding |
| Ontology | molecular_function |
| Synonym | None |
| Major function | Binding to C-X-C chemokines, a subclass of chemokines with one amino acid between the first two cysteines |
| Definition source | QuickGO |
| Related chemokine subclass | C-X-C chemokines (e.g., CXCL8, CXCL12) |
| Representative binding proteins | CXCR1, CXCR2, CXCR4, DARC, tick evasins, viral chemokine-binding proteins |
| Pathological relevance | Inflammation, cancer, osteoarthritis, pathogen immune evasion |
What Is GO:0019958?
According to the Gene Ontology, C-X-C chemokine binding (GO:0019958) is the molecular function of binding to a C-X-C chemokine, where C-X-C chemokines are defined by a single amino acid between the first two cysteines of the characteristic four-cysteine motif. This function is distinct from binding to C-C chemokines, which lack the intervening residue. The term encompasses interactions with both signaling receptors and non-signaling decoy receptors, as well as pathogen-encoded chemokine-binding proteins.
Why Is C-X-C chemokine binding Important in Cell Biology?
C-X-C chemokine binding is a central node in immune regulation and disease pathogenesis. It governs the recruitment of neutrophils, lymphocytes, and other leukocytes to sites of inflammation, and it modulates angiogenesis and tumor progression. Dysregulated C-X-C chemokine binding contributes to chronic inflammatory diseases, cancer chemoresistance, and osteoarthritis. Furthermore, pathogens exploit this function by expressing chemokine-binding proteins that subvert host immunity, as seen in tick evasins and viral proteins. Therefore, understanding the molecular determinants of C-X-C chemokine binding is essential for developing targeted therapeutics and for interpreting CRISPR-based screens of chemokine-receptor interactions.
• C-X-C chemokine binding controls directed leukocyte migration during inflammation and infection.
• Atypical receptors like DARC act as decoys that modulate chemokine availability and can influence tumor growth.
• Tick evasins with engineered C-X-C chemokine-binding specificity are promising anti-inflammatory biologics.
• Viral chemokine-binding proteins provide insights into immune evasion mechanisms and potential drug scaffolds.
• In colorectal cancer, C-X-C chemokine binding via CCR4 promotes 5-fluorouracil resistance through MRP1 membrane translocation.
• Keratin 17 and hnRNP K regulate C-X-C chemokine gene expression in skin tumor keratinocytes, linking binding to tumorigenesis.
• Osteoarthritis involves altered C-X-C chemokine signaling, making binding interactions potential therapeutic targets.
• In situ binding assays enable direct visualization of chemokine interactions with endothelial cells.
• Structure-activity studies of chemokines reveal determinants of receptor binding specificity.
• CRISPR screens can identify genes required for C-X-C chemokine binding and downstream signaling.
Molecular Mechanism of C-X-C chemokine binding
Chemokine Recognition and Binding Interface
In simple terms: The C-X-C chemokine docks onto a receptor or binding protein through a specific surface patch.
C-X-C chemokines adopt a conserved tertiary structure stabilized by disulfide bonds, with the N-terminal region and the loop following the second cysteine forming the primary receptor-binding epitope. Binding to classical receptors such as CXCR1 and CXCR2 involves two sites: the chemokine N-terminus interacts with the receptor N-terminal domain, while the chemokine core binds to the receptor extracellular loops. This two-step mechanism ensures high specificity and allows discrimination between C-X-C and C-C chemokines.
Receptor Activation and Signaling
In simple terms: Once bound, the receptor changes shape and triggers signals inside the cell.
For G-protein-coupled C-X-C chemokine receptors, ligand binding induces conformational changes that promote guanine nucleotide exchange on Gαi subunits, leading to inhibition of adenylyl cyclase and activation of downstream effectors such as PI3K and MAPK. This signaling cascade drives chemotaxis, integrin activation, and gene expression. In contrast, atypical receptors like DARC bind C-X-C chemokines without activating G proteins, functioning as scavengers or transporters.
Atypical and Decoy Binding Proteins
In simple terms: Some proteins bind chemokines just to soak them up, not to send signals.
The Duffy antigen receptor for chemokines (DARC) binds both C-X-C and C-C chemokines with high affinity but lacks classical signaling capacity, thereby modulating chemokine gradients and inflammation. Pathogen-derived evasins, such as those from ticks, have evolved to bind C-X-C chemokines with high specificity, effectively neutralizing them and suppressing host immune responses. Viral chemokine-binding proteins similarly sequester chemokines to evade immune detection.
Regulation of C-X-C Chemokine Binding
In simple terms: Cells control how much binding happens by changing receptor levels or chemokine availability.
C-X-C chemokine binding is regulated at multiple levels, including transcriptional control of chemokine and receptor genes, post-translational modifications, and receptor internalization. For instance, keratin 17 and hnRNP K regulate C-X-C chemokine gene expression in skin tumor keratinocytes, affecting the local concentration of ligands available for binding. In osteoarthritis, inflammatory cytokines modulate the expression of C-X-C chemokines and their receptors, altering binding dynamics. Additionally, decoy receptors like DARC can be upregulated to buffer excess chemokines.
Key Genes Involved in GO:0019958 C-X-C chemokine binding
The following genes encode proteins that bind C-X-C chemokines or regulate their availability, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CXCR1 | G-protein-coupled receptor for CXCL8 and other C-X-C chemokines | Neutrophil recruitment; inflammation; cancer progression |
| CXCR2 | G-protein-coupled receptor for multiple C-X-C chemokines | Angiogenesis; neutrophil trafficking; tumor microenvironment |
| CXCR4 | Receptor for CXCL12 | Stem cell homing; cancer metastasis; HIV entry |
| ACKR1 (DARC) | Atypical chemokine receptor that binds C-X-C and C-C chemokines | Chemokine scavenging; inflammation resolution; malaria susceptibility |
| CXCL8 (IL-8) | C-X-C chemokine ligand | Neutrophil chemotaxis; inflammatory diseases; cancer |
| CXCL12 (SDF-1) | C-X-C chemokine ligand | Embryonic development; hematopoiesis; cancer metastasis |
| CXCL17 | C-X-C chemokine ligand | Mucosal immunity; tumor-associated macrophage function |
| CXCL22 | C-X-C chemokine ligand | Chemoresistance in colorectal cancer via CCR4 |
| CCR4 | Receptor for CXCL17/CXCL22 (atypical binding) | Tumor-associated macrophage-mediated drug resistance |
| KRT17 | Keratin 17, regulates C-X-C chemokine gene expression | Skin tumorigenesis; inflammation |
| HNRNPK | hnRNP K, RNA-binding protein regulating chemokine expression | Transcriptional and post-transcriptional control |
| ATF6 | Transcription factor in unfolded protein response | Chemoresistance axis with GRP78 |
| HSPA5 (GRP78) | Chaperone involved in ER stress | Chemoresistance; protein folding |
| Evasin proteins (tick) | C-X-C chemokine-binding proteins from ticks | Anti-inflammatory biologics; specificity engineering |
| Viral chemokine-binding proteins | Pathogen-derived C-X-C chemokine binders | Immune evasion; drug design |
| CXCL10 | C-X-C chemokine ligand | Th1 responses; viral infections; autoimmunity |
| CXCL1 | C-X-C chemokine ligand | Neutrophil recruitment; inflammation |
| CXCL5 | C-X-C chemokine ligand | Angiogenesis; tumor progression |
How Is C-X-C chemokine binding Regulated?
C-X-C chemokine binding is regulated by the expression levels of both chemokines and their binding partners, as well as by post-translational modifications and receptor trafficking. In skin tumor keratinocytes, keratin 17 and hnRNP K coordinately regulate C-X-C chemokine gene expression, thereby influencing the pool of ligands available for binding. In osteoarthritis, pro-inflammatory cytokines such as IL-1β and TNF-α upregulate C-X-C chemokines and their receptors, enhancing binding and downstream catabolic signaling. Additionally, atypical receptors like DARC can be induced to sequester chemokines, providing a negative feedback mechanism. Pathogen-derived evasins are regulated by their own promoters and can be engineered for altered specificity.
C-X-C chemokine binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CXCL17/CXCL22-CCR4 axis | Colorectal cancer 5-FU resistance | Knockout of CCR4 in macrophages; overexpression of CXCL17/22 in tumor cells |
| CXCR4 | Cancer metastasis | Knock-in of CXCR4 mutations; knockout in cancer cell lines |
| ACKR1 (DARC) | Inflammation and malaria susceptibility | Knockout and overexpression in endothelial cells |
| KRT17 | Skin tumorigenesis | Keratinocyte-specific knockout; point mutations in KRT17 |
| CXCL8 | Inflammatory diseases | Knockout in immune cells; reporter knock-in for expression |
Cancer Chemoresistance and Tumor Microenvironment
C-X-C chemokine binding plays a critical role in tumor progression and drug resistance. In colorectal cancer, tumor-associated macrophages promote 5-fluorouracil resistance by facilitating MRP1 membrane translocation through an intercellular CXCL17/CXCL22-CCR4-ATF6-GRP78 axis. This highlights how C-X-C chemokine binding on macrophages and tumor cells can reprogram the microenvironment to support chemoresistance. Additionally, CXCR4 binding to CXCL12 promotes metastasis in breast and other cancers.
Osteoarthritis and Inflammatory Joint Disease
Osteoarthritis involves chronic low-grade inflammation driven in part by C-X-C chemokines. Binding of C-X-C chemokines to their receptors on chondrocytes and synoviocytes promotes matrix metalloproteinase expression and cartilage degradation. Targeting these interactions may offer disease-modifying strategies.
Pathogen Immune Evasion
Viruses and parasites encode C-X-C chemokine-binding proteins that sequester chemokines and dampen host immune responses. Tick evasins, for example, bind C-X-C chemokines with high specificity and are being developed as anti-inflammatory therapeutics. Viral chemokine-binding proteins similarly interfere with leukocyte recruitment, contributing to pathogenesis.
From C-X-C chemokine binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of CXCR4 affect C-X-C chemokine binding and metastasis? | CXCR4 knockout in cancer cell lines or mouse models |
| How do point mutations in DARC alter chemokine binding specificity? | Point-mutation knock-in of ACKR1 in cell lines |
| Can a tagged C-X-C chemokine receptor be used to track binding dynamics? | Knock-in of fluorescent or epitope tags on CXCR4 |
| Does overexpression of CXCL17 promote chemoresistance? | Overexpression of CXCL17 in colorectal cancer cells |
| Which genes are essential for C-X-C chemokine binding in immune cells? | CRISPR library screening in primary macrophages |
| How does keratin 17 regulate C-X-C chemokine gene expression? | KRT17 knockout and overexpression in keratinocytes |
How to Study the C-X-C chemokine binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| In situ binding assay | Chemokine binding to cells or tissue sections | Endothelial cell-chemokine interactions |
| Surface plasmon resonance | Binding affinity and kinetics | Receptor-ligand specificity |
| CRISPR knockout screen | Genes required for binding or signaling | Identify novel regulators |
| RNA-seq | Gene expression of chemokines and receptors | Tumor microenvironment profiling |
| Proteomics | Protein abundance and modifications | Post-translational regulation of binding |
| Flow cytometry | Cell surface binding of fluorescent chemokines | Receptor expression and binding capacity |
| Chemotaxis assay | Functional migration in response to chemokines | Leukocyte recruitment |
| Isothermal titration calorimetry | Thermodynamics of binding | Decoy receptor characterization |
In Situ Binding Assays
In situ binding assays allow visualization of chemokine interactions with endothelial cells or tissue sections. Rot (2003) described a method for studying chemokine binding to endothelial cells, which can be adapted to C-X-C chemokines. This technique is valuable for assessing binding specificity and competition.
Surface Plasmon Resonance and Biophysical Binding Assays
Surface plasmon resonance (SPR) and isothermal titration calorimetry provide quantitative measures of binding affinity and kinetics between C-X-C chemokines and their receptors or decoy proteins. These methods have been used to characterize DARC binding to C-X-C chemokines and to engineer tick evasins with altered specificity.
CRISPR Screens and Functional Genomics
CRISPR knockout and activation screens can identify genes required for C-X-C chemokine binding and downstream signaling. For example, a screen in skin tumor keratinocytes could reveal regulators of C-X-C chemokine gene expression. Such screens are powerful for discovering novel binding partners or modifiers.
Transcriptomics and Proteomics
RNA-seq and proteomics can quantify expression of C-X-C chemokines and their receptors under different conditions. In colorectal cancer, transcriptomic analysis revealed the CXCL17/CXCL22-CCR4-ATF6-GRP78 axis. Proteomic approaches can identify post-translational modifications that affect binding.
How CRISPR Can Be Used to Study GO:0019958 C-X-C chemokine binding
Knockout
CRISPR knockout of genes encoding C-X-C chemokines, their receptors, or binding proteins can abolish specific binding interactions. For example, knocking out CXCR4 in cancer cells eliminates CXCL12 binding and downstream signaling, enabling causal tests of metastasis. Knockout of ACKR1 (DARC) in endothelial cells can reveal its role in chemokine scavenging.
Point Mutation
Point mutations can be introduced to dissect binding interfaces. For instance, mutating key residues in the N-terminal region of a C-X-C chemokine or in the receptor extracellular loops can alter binding affinity and specificity. Such models are useful for validating structural predictions.
Knock-in
Knock-in of tagged versions of C-X-C chemokine receptors (e.g., GFP or HA tags) allows real-time tracking of binding and trafficking. Knock-in of disease-associated mutations, such as those in ACKR1, can model altered chemokine binding in inflammation.
Overexpression
Overexpression of C-X-C chemokines or their receptors can amplify binding signals and mimic pathological states. For example, overexpression of CXCL17 in colorectal cancer cells promoted chemoresistance via CCR4 binding. Overexpression of tick evasins in mammalian cells can be used to produce recombinant binding proteins.
How EDITGENE Supports C-X-C chemokine binding Research
Researchers studying C-X-C chemokine binding-related genes often need to determine whether a candidate gene is causally involved in chemokine recognition, signaling, or disease progression. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such investigations, from knockout to precise point mutations and overexpression.
Contact EDITGENE today to design your custom CRISPR model for C-X-C chemokine binding research.
Frequently Asked Questions About C-X-C chemokine binding
What is C-X-C chemokine binding?
C-X-C chemokine binding (GO:0019958) is the molecular function of binding to a C-X-C chemokine, a subclass of chemokines with one amino acid between the first two cysteines of the four-cysteine motif.
What genes are involved in C-X-C chemokine binding?
Key genes include CXCR1, CXCR2, CXCR4, ACKR1 (DARC), and various C-X-C chemokine ligands such as CXCL8, CXCL12, and CXCL17.
How is C-X-C chemokine binding studied?
Common methods include in situ binding assays, surface plasmon resonance, flow cytometry, and CRISPR screens.
What is the difference between C-X-C and C-C chemokine binding?
C-X-C chemokines have one amino acid between the first two cysteines, while C-C chemokines have adjacent cysteines; binding specificity is determined by receptor-ligand interactions.
Which diseases are associated with C-X-C chemokine binding?
Cancer chemoresistance, osteoarthritis, and pathogen immune evasion are linked to C-X-C chemokine binding.
What are tick evasins?
Tick evasins are proteins that bind C-X-C chemokines with high specificity and are studied for anti-inflammatory therapy.
How does DARC bind C-X-C chemokines?
DARC (ACKR1) binds C-X-C and C-C chemokines as an atypical decoy receptor, modulating chemokine gradients without G-protein signaling.
Can CRISPR be used to study C-X-C chemokine binding?
Yes, CRISPR knockout, knock-in, and overexpression models enable causal studies of genes involved in C-X-C chemokine binding.
What is the role of C-X-C chemokine binding in cancer?
It promotes tumor progression and chemoresistance, for example via the CXCL17/CXCL22-CCR4 axis in colorectal cancer.
How is C-X-C chemokine binding regulated?
Regulation occurs at transcriptional and post-translational levels, including by keratin 17 and hnRNP K in skin tumors.
Conclusion
C-X-C chemokine binding (GO:0019958) is a fundamental molecular function that governs immune cell trafficking, inflammation, and cancer progression. Its specificity is determined by the structural features of C-X-C chemokines and their receptors, and it is exploited by pathogens for immune evasion. Understanding the genes and mechanisms involved provides opportunities for therapeutic intervention. EDITGENE offers comprehensive CRISPR services to support research on C-X-C chemokine binding, from knockout to overexpression and library screening.
References
- 1. Rot A. 2003. In situ binding assay for studying chemokine interactions with endothelial cells.. J Immunol Methods 273(1-2):63-71 PMID: 12535798
- 2. Zhang L et al.. 2023. Tumor-associated macrophages confer colorectal cancer 5-fluorouracil resistance by promoting MRP1 membrane translocation via an intercellular CXCL17/CXCL22-CCR4-ATF6-GRP78 axis.. Cell Death Dis 14(9):582 PMID: 37658050
- 3. Clark-Lewis I et al.. 1995. Structure-activity relationships of chemokines.. J Leukoc Biol 57(5):703-11 PMID: 7759949
- 4. Lee AW et al.. 2019. A knottin scaffold directs the CXC-chemokine-binding specificity of tick evasins.. J Biol Chem 294(29):11199-11212 PMID: 31167786
- 5. Szabo MC et al.. 1995. Chemokine class differences in binding to the Duffy antigen-erythrocyte chemokine receptor.. J Biol Chem 270(43):25348-51 PMID: 7592697
- 6. Chung BM et al.. 2015. Regulation of C-X-C chemokine gene expression by keratin 17 and hnRNP K in skin tumor keratinocytes.. J Cell Biol 208(5):613-27 PMID: 25713416
- 7. Lalani AS et al.. 1999. Evasion and exploitation of chemokines by viruses.. Cytokine Growth Factor Rev 10(3-4):219-33 PMID: 10647778
- 8. Malfait AM. 2016. Osteoarthritis year in review 2015: biology.. Osteoarthritis Cartilage 24(1):21-6 PMID: 26707989
